Together with point mutations, homozygous deletions or duplications in PARK2 are responsible for the majority of autosomal recessive juvenile Parkinsonism. It is debated, however, whether heterozygous carriers of these mutations are at increased risk of Parkinson's disease (PD). Our goal was to determine whether heterozygous carriers of copy number variants (CNVs) affecting exons of the PARK2 gene are at risk of PD that is greater than that of non-carriers. We searched for CNVs affecting exons of PARK2 in a sample of 105 749 genotyped Icelanders. In total, 989 carriers, including 24 diagnosed with PD, were identified. The heterozygous carriers were tested for association in a sample of 1415 PD patients and 40 474 controls ≥65 years of age. PD patients were more often heterozygous carriers of PARK2 CNVs than controls [odds ratio (OR) = 1.69, P = 0.03] and compound heterozygous PD patients for a CNV and a missense mutation were not found. Furthermore, we conducted a meta-analysis of studies reporting on case-control samples screened for heterozygous PARK2 CNVs. Ten studies were included in the final analysis, with 4538 cases and 4213 controls. The pooled OR and P-value for the published and Icelandic results showed significant association between PARK2 CNVs and risk of PD (OR = 2.11, P = 2.54 × 10
Introduction
Parkinson's disease (PD), the second most common progressive neurodegenerative disorder, was long believed to be of non-genetic, sporadic origin. However, in recent years, the understanding of the pathogenesis of PD has changed. Research has revealed rare monogenic forms of PD that are inherited in either an autosomal dominant or an autosomal recessive manner. Moreover, several common sequence variants conferring low or modest risk of PD have been found (1) .
Four genes have already been identified contributing to autosomal recessive early onset Parkinsonism, a subtype of PD. These are PARK2 at the PARK2 locus (2) (OMIM*602544), PINK1 at PARK6 (3) (OMIM*608309), DJ-1 at PARK7 (4) (OMIM*602533) and ATP13A2 at PARK9 (5) (OMIM* 610513). Mutations in PARK2, an E3 ubiquitin ligase (6) , are responsible for 50% of familial early onset PD (7, 8) .
PARK2-linked PD was first identified in a consanguineous Japanese family by Yamamura and colleagues (2) right before the gene was mapped to chromosome 6q25.2-q27 (9) . PARK2 has a high mutation rate (10, 11) and is located in an unstable region in the genome. Thus, >100 putatively pathogenic mutations have been reported worldwide (12) (13) (14) (15) . Among them are point mutations and exon rearrangements, which contribute equally to the PARK2 mutation spectrum (1, (16) (17) (18) . The classical view is that carriers of one risk allele are not affected although this view is debated (19) . Copy number variants (CNVs) constitute a particular challenge in genetic association studies and the impact of CNVs affecting PARK2 in heterozygous carriers in large samples remains to be studied (20) .
Our goal was to ascertain the frequency of PARK2 mutations in a large genotyped sample, patients as well as controls and thereby determine the risk conferred by PARK2 CNVs in heterozygous carriers. The large genotyped sample at deCODE in which genotypes are long-range-phased (LRP) (21) (22) (23) and into which variants from a large whole genome sequencing effort have been imputed (24, 25) was mined. The LRP sample was most helpful in identifying and excluding possible compound heterozygous carriers of mutations in PARK2. To augment our results, a meta-analysis of reported studies focusing on heterozygous PARK2 CNV carriers was performed.
Results
The CNV analysis of 1415 PD patients and 104 320 controls revealed several large exon rearrangements in PARK2 as well as smaller deletions and duplications affecting predominantly exon 2 (Supplementary Material, Figure S1 ). After visual inspection of PennCNV calls, 989 calls were confirmed and included in further analysis. In detail, 24 (1.69%) PD patients and 965 (0.92%) controls were carriers of an exon rearrangement. The control frequency remained comparable when participants younger than 65 were excluded, 373/40 474 (0.91%). This is in keeping with Kay et al. (20) , who found heterozygous PARK2 CNVs in 0.93% carrier frequency. In addition, among the patients we detected two homozygous CNV carriers, one homozygous for an exon 2 deletion and another homozygous for a large duplication spanning the gene. In the population sample, two siblings homozygous for an exon 2 duplication were found. Both are younger than 65 and have not developed PD.
As expected, homozygous CNVs affecting PARK2 were associated with PD (P = 0.001). More noteworthy, our data demonstrate that heterozygous CNV carriers are at risk of developing PD [odds ratio (OR) = 1.69, P = 0.03] ( Table 1) .
To address whether compound heterozygous CNV carriers could explain the association, we analyzed data derived from 2261 whole genome sequenced subjects whose genotypes had been imputed into LRP haplotypes (21) (22) (23) Table 2) . Among those, a p.Met327Ile variant is novel and here exclusively found in control subjects. The remaining seven variants were found both in cases and controls and have previously been reported elsewhere (Table 2 ). Variants p.Ser167Asn, p. Val380Leu and p.Asp394Asn are common benign polymorphisms (29) , whereas p.Ala82Glu, p.Arg402Cys and p.Pro409Leu may confer risk of PD (30) . One of the sequence variants, p. Arg275Trp, was predicted to be deleterious by both SIFT (http ://sift.jcvi.org/) and PolyPhen2 (http://genetics.bwh.harvard.edu/ pph2/) and had been classified as a causative or susceptibility variant in earlier studies (15, (31) (32) (33) (34) . Consistent with that, under a recessive model, a suggestive association with p.Arg275Trp was detected (OR = 23.1, P = 0.079) in our sample. A burden test of missense mutations did not reveal significant association with PD in keeping with recent studies (26) .
Through imputation, we only capture variants down to frequencies of ∼0.01%. To search for very rare causative variants that contribute to the risk, we Sanger sequenced PD subjects carrying CNVs in PARK2 and all patients carrying the p.Arg275Trp allele. This effort did not uncover additional known or novel PARK2 mutations.
The LRP genotypes allow for determining whether mutations in carriers of two PARK2 mutations are on the same chromosome (21, 24) . No PD patients were found to be compound heterozygous for the rare allele of p.Arg275Trp and a CNV affecting PARK2. Two controls, siblings older than 64, were compound heterozygous for an exon 2 duplication and an Arg275Trp mutation (Supplementary Material, Table S1 ).
Meta-analysis
A comprehensive review of 130 articles reporting on CNVs in PARK2 revealed 10 studies that fulfilled the inclusion criteria for a meta-analysis. In total, data on 8751 individuals (4538 cases and 4213 controls) were used. In the combined analysis, significant association was observed between carrying one copy of PARK2 CNV and PD (OR = 2.53, P = 1.67 × 10 −5 ). Including the results from Iceland, the significance increased (OR = 2.11, P = 2.54 × 10 −6 ). Results are summarized in Table 3 .
Discussion
This study focused on the identification of heterozygous CNVs in the PARK2 gene with the purpose of evaluating their contribution to the pathogenesis of PD. Our data demonstrate that heterozygous CNV carriers are at risk of PD (OR = 1.69, P = 0.03). Also, our comprehensive attempts to exclude compound heterozygotes support the notion that haploinsufficiency is a more likely explanation than compound heterozygosity through unidentified recessive mutations. Furthermore, our association results are supported by our meta-analysis of reported studies (OR = 2.11, P = 2.54e × 10 −6 ).
So far, most studies evaluating the risk of PARK2 mutations in heterozygous carriers focus on SNPs rather than CNVs (26, 27, 40, 42, 45) . However, heterozygous CNVs in PARK2 might be even more pathogenic than heterozygous point mutations (38) . A few groups have focused on CNVs. In agreement with our results, two reports indicate that heterozygous mutations in PARK2 associate with increased risk of PD (37, 38) , albeit others found no evidence for an association (20, 46, 47) . One possible reason for the diverging results could be the small sample sizes of these studies. The low frequency of CNVs renders a large sample set, as we used, essential for a reliable assessment of the disease risk.
Not only association studies but also examinations of families have yielded conflicting results. Heterozygous family members of homozygous carriers have been described with mild PD signs of late onset (15, (48) (49) (50) , whereas another group found no typical clinical signs of the disease (47) . A recent study showed that typical PARK2-associated symptoms, such as dystonia and dyskinesia, correlate with the number of mutated PARK2 alleles (51) . Furthermore in comparison to homozygous carriers, characterized by an onset before the age of 40 years, some groups showed that heterozygous carriers of CNVs as well as point mutations are associated with a later onset (36,42,52-54). Still, an earlier age at onset for PARK2 mutation carriers compared with that of individuals without mutations in PARK2 is suspected (31, 53, 55) .
The notion that heterozygous carriers may be at increased risk of PD is also supported by neuroimaging and electrophysiological findings. Preclinical changes such as reduced fluorodopa uptake in the striatum of asymptomatic heterozygous mutation carriers were connected to development of PD later in life (32, (56) (57) (58) .
As shown before (46) , compound heterozygous mutations in PARK2 exist and may explain the disease in a fraction of mutation carriers. However, there are few statistical methods for analyzing the role of compound heterozygous mutations in disease, especially when such mutations are rare. The major barrier is that phase information is required to determine whether both gene copies are affected and phasing rare variants is difficult. Thus, phase determination is important in carriers of two mutations as both mutations may have been inherited from the same parent. In most PD studies, phasing is impossible, parents of cases are usually not genotyped and many of the patients are sporadic cases. Thus, determining whether two or one mutations are on the same chromosome is difficult and uncertainty about the phase of strings of SNPs creates complications in genetic analysis. Most available methods can only phase a small number of SNPs effectively and become unreliable when applied to SNPs spanning many linkage disequilibrium blocks. By means of LRP haplotypes (21), we were able to determine the phase of alleles likely to confer risk of PD. Hence, to further corroborate our results, samples from the Icelandic subjects heterozygous for the PARK2 CNVs were screened for missense mutations in the PARK2 gene. Of the uncovered coding variants, only the p.Arg275Trp mutation was considered causal (10, 33, 59 ) and the search for compound heterozygotes revealed none of our cases to carry a CNV and a p.Arg275Trp mutation in trans. Therefore, we conclude that the detected OR of 1.69 in our sample set is mediated through dosage of single heterozygous mutations (CNVs). Haploinsufficiency, a dominant-negative effect or gain of function, is the most likely pathogenic mechanism behind it (16, 60, 61) . Heterozygous PARK2 CNV carriers in the large Icelandic sample are at risk of developing PD and our meta-analysis further supports the involvement of PARK2 CNVs in heterozygous carriers. To date, most studies focusing on subjects heterozygous for CNVs and missense variants in PARK2 are limited by modest sample sizes. Still, our literature search resulted in a combined sample set of 4538 cases and 4213 controls. Tested for association, the OR was even higher than in Iceland, supporting our results. However, we have to keep in mind that sampling differs between groups. Furthermore, there has been a continuous increase in the quality of copy number analysis tools over the past years, and recent studies suggest that some earlier studies may have included false-positive calls. Publication bias is also of concern in meta-analysis (62) . Most importantly, not all the meta-analysis samples were screened for missense mutations. Hence, compound heterozygous PARK2 mutation carries might have been included in previous datasets.
With regard to genetic testing and counseling, our results do not support routine screening because the disease risk for heterozygous CNV carriers is low. However, with the increasing availability of genetic testing for familial and sporadic PD, a better understanding of the inheritance pattern and the penetrance will help to interpret the test results. In particular, those with a family history of PD and identified PARK2 mutations in a first-degree relative may benefit from genetic testing. Albeit preventive therapy is currently not available, genetic testing may allow the mitigation of uncertainty and help to interpret any initial clinical problems, enabling early intervention in mutation carriers, if necessary.
In conclusion, we provide further evidence in support of our opinion that heterozygous PARK2 CNV carriers are at increased risk of developing PD. The mutations may act as susceptibility factors or disease modifiers and might further contribute to the heritability of familial and sporadic PD. Thus, the impact of heterozygous CNVs in PARK2 should not be underestimated and should be the focus of future investigation. It is important to further elucidate their role in PD to provide an accurate diagnosis and counseling of mutation carriers.
Materials and Methods

Patients and controls
The ascertainment of Icelandic PD patients has been described in detail elsewhere (63) (64) (65) . In brief, patients included were enrolled from two studies. The first study identified patients through genealogical data based on censuses, church books, the national registry or obituaries and information that was collected between 1953 and 1963. The second study included patients that were recruited through an ongoing, population-based study at deCODE. Since 1994, patients were identified from the Icelandic Parkinson's Disease Society, neurologists, general practitioners, the Resident Assessment Instrument used in nursing homes to estimate dependency (66) and records of prescriptions for levodopa and other drugs commonly given to patients with PD.
PD patients underwent a detailed clinical examination by a movement disorder specialist and were included in the study if they had at least two of the following cardinal signs: tremor, rigidity, bradykinesia or postural instability (67) , and other causes of Parkinsonism were excluded.
Genotyping
In total, 105 749 DNA samples were genotyped using IlluminaHumanHap and IlluminaOmniExpress arrays. Of those, 93 698 could be LRP, which is necessary for effective imputation of rare variants. Sequence variants from the whole genome sequencing project at deCODE, including 2261 subjects sequenced on average at 15×, were imputed into the large sample (24, 25) . Of 1415 genotyped PD samples, 1387 were imputed. The genotyped controls were population controls recruited through other studies at de-CODE genetics.
All biological samples were collected after approval had been obtained from the National Bioethics Committee and the Icelandic Data Protection Authority. Written informed consent was provided by the participants. In order to protect personal information on health and disease, all samples were encrypted through a third independent party in accordance with the regulations of the Icelandic Data Protection Committee (68) .
Detection of copy number variation
The PennCNV caller, described in detail elsewhere (69) , was used for searching the 105 749 genotyped subjects for CNVs. The algorithm uses signal intensity data from SNP probes to estimate the copy number of genomic regions. The approach is based on a hidden Markov model, a statistical method, which combines several components, to estimate the probability of the allelic state to be true and generate the most reliable CNV calls. The following measurements were included: the log R ratio (normalized measure of total signal intensity at each SNP), the B allele frequency (normalized measure of allelic intensity ratio at each SNP), the distance between neighboring SNPs ( probability of having a copy number state change) and the population frequency of the B allele. Subsequently, the software calculates whether the intensity is above or below a given empirical threshold. Only CNVs spanning 10 or more consecutive markers were considered true after visual inspection. Frequencies of PARK2 CNVs found in samples genotyped using different Illumina genotyping chips are shown in Supplementary Material, Table S2 .
Sanger sequencing
In order to identify additional disease causing mutations that remained undetected through imputation, we sequenced the entire PARK2 (NM_004562.2) coding sequence (exons 1-12) and flanking intronic regions (Supplementary Material, Table S3 ) in all PD patients heterozygous for PARK2 deletions or duplications and all patients carrying the rare allele of the identified missense mutation (rs1621268). Therefore, genomic DNA was extracted from peripheral blood using standard methods. Dye-terminator Sanger sequencing was performed with the Applied Biosystems BigDye Terminator v3.1 Cycle Sequencing Kit, with Agencourt Ampure XP and Agencourt CleanSeq for cleanup of the polymerase chain reaction (PCR) and cycle-sequencing product, respectively. AmpureXP and CleanSeq bead cleaning was performed on a Zymark Sciclone ALH-500 liquid-handling robot system. Tray dilutions for PCR setup and cycle-sequencing setup were prepared on a Packard MultiprobeII HTEX liquid-handling robot system, and genomic DNA and PCR product were transferred into their respective trays using the Zymark Sciclone ALH-500. PCR and cycle-sequencing reactions were performed on MJ Research PTC-225 thermal cyclers. Subsequently, electropherograms were analyzed with Applied Biosystems 3730xl DNA analyzers.
Prediction of functional effects of coding variants
In silico prediction for a possible change in protein function was performed by SIFT (http://sift.jcvi.org/) (70) and PolyPhen2 (http://genetics.bwh.harvard.edu/pph2/) (71).
Literature review for meta-analysis
Published articles reporting on heterozygous PARK2 CNV carriers were identified through computer searches of the Medline database (http://www.ncbi.nlm.nih.gov/pubmed/) and the PD mutation database (www.molgen.ua.ac.be/PDmutDB). Combinations of the search terms 'PD or Parkinson's disease', 'Parkin or PARK2', 'CNVs or copy number variations' and 'heterozygous' resulted in 127 articles. Furthermore, our literature list was supplemented by a manual search of references cited in published articles, resulting in three additional publications.
Of these 130 studies, 32 were excluded due to improper content, leaving 98 potential literature citations for abstract and publication review. Following this step, studies were included in our analysis when exact numbers of heterozygous CNVs were reported for cases and controls.
In total, 10 studies met the full inclusion criteria and provided sufficient information to estimate study-specific OR and 95% confidence interval (CI) by Fisher's exact test. On the whole, 8751 individuals (4538 cases and 4213 controls) were enrolled. To estimate the pooled OR and P-value for all non-Icelandic strata, the exact Mantel-Haenszel method was used. For the Icelandic study, which included related individuals, an empirical P-value was obtained based on 500 000 drop-down simulations through the Icelandic genealogy. The published and Icelandic results were combined using standard, fixed effects, inverse-variance weighted meta-analysis.
Supplementary Material
Supplementary Material is available at HMG online. 
